Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;16(6):1433-1439.
doi: 10.1111/iwj.13210. Epub 2019 Sep 2.

Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review

Giovanni Presta  1 , Andrea Puliatti  2 , Loris Bonetti  3 , Angela Tolotti  3 , Davide Sari  4 , Dario Valcarenghi  3
Affiliations
Review

Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review

Giovanni Presta et al. Int Wound J. 2019 Dec.

Abstract

One of the principal side effects in patients that receive radiotherapy is radiodermatitis. Radiodermatitis can be highly invalidating for patients, causing pain, ulceration, swelling, and increased infection risk, with a negative effect on the quality of life, requiring dressings and medications. Therapeutic approaches reported so far in the literature have not proved to be effective in treating radiodermatitis. Therefore, new approaches are needed to deal with these side effects more effectively. The aim of the study was to evaluate the effectiveness of hyaluronic acid gel (HAG) (Jalosome soothing gel) for the treatment of a case of radiodermatitis. This is a case study of a patient affected by squamous cell carcinoma at the tongue base, who was treated with head and neck radiotherapy associated with the administration of cetuximab. About 1 month after this therapy was started the patient developed radiodermatitis, which did not regress with standard treatment. Therefore, HAG was applied once a day for about 20 days. The regression of radiodermatitis was measured using the Radiation Toxicity/Oncology Grading scale, pain relief was measured with a numerical scale, and patient satisfaction was done through a semi-structured interview. The patient presented a dramatic reduction of skin toxicity, which had been resistant to all previous therapeutic approaches. Pain, which was severe at the beginning, gradually disappeared. The patient showed great satisfaction for the reduction of pain and the regression of the radiodermatitis. The effectiveness of HAG appears to be promising for the treatment of radiodermatitis.

Keywords: cetuximab; head and neck cancer; hyaluronic acid gel; radiodermatitis; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest and no relationship whatsoever with the company that produces Jalosome soothing gel.

Figures

Figure 1
Figure 1
Condition of the skin on second week of February before the application of HAG (with standard medication). HAG, hyaluronic acid gel
Figure 2
Figure 2
Condition of the skin on third week of February before application of HAG (with standard medication). HAG, hyaluronic acid gel
Figure 3
Figure 3
Condition of the skin on sixth week of February after 3 days application of HAG. HAG, hyaluronic acid gel
Figure 4
Figure 4
Condition of the skin at the end of treatment with HAG. HAG, hyaluronic acid gel
See this image and copyright information in PMC

References

    1. Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and chronic cutaneous reactions to ionizing radiation therapy. Dermatol Ther (Heidelb). 2016;6:185 206‐185 206. 10.1007/s13555-016-0120-y. - DOI - PMC - PubMed
    1. Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016;17:277‐292. 10.1007/s40257-016-0186-4. - DOI - PubMed
    1. Hickok JT, Morrow GR, Roscoe JA, Mustian K, Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage. 2005;30(5):433‐442. - PubMed
    1. McQuestion M. Evidence‐based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011;27(2):e1‐e17. 10.1016/j.soncn.2011.02.009. - DOI - PubMed
    1. Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation‐induced skin reactions: a systematic review of the literature. Curr Oncol. 2010;17(4):94‐112. - PMC - PubMed